% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

ricardouno 6 posts  |  Last Activity: Jun 2, 2015 9:47 PM Member since: Jun 5, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ricardouno ricardouno Jun 2, 2015 9:47 PM Flag

    From American Banking & Market News 6/2:

    Stock analysts at HC Wainright set a $65.00 price objective on shares of Seattle Genetics (NASDAQ:SGEN) stock in a report issued on Tuesday. The firm currently has a a “buy” rating on the stock.

    In other Seattle Genetics news, Director Felix Baker purchased 950,886 shares of Seattle Genetics stock in a transaction that occurred on Thursday, May 21st. The shares were purchased at an average price of $42.49 per share, for a total transaction of $40,403,146.14. The purchase was disclosed in a document filed with the SEC....

  • Reply to

    Baseline characteristics?

    by jwharrison02 May 31, 2015 10:39 AM
    ricardouno ricardouno May 31, 2015 3:01 PM Flag

    Sets the stage for trials of combined therapy with drugs that boost the immune response to the vaccine

  • Reply to

    CD30 Depletion Therapy

    by ricardouno May 13, 2015 7:26 AM
    ricardouno ricardouno May 14, 2015 7:49 AM Flag


    Perhaps, then, "CD30 Cell Depletion Therapy" might be more descriptively accurate......with the serum level of soluble CD30 being the related possible bio-marker of effect.

    Of course, SGEN's ADC theoretically offers a much simpler " right off the shelf" therapy addressing of the basic pathophysiology as compared to a CAR T cell approach.

    The following statement is absolute TOTAL speculation........... but, the addressable total population of such "potential" therapies in auto-immune and inflammatory disorders is logarithmic relative to HD alone.


    Disclosure and warning: Ricardo has lost it. The above could be reality or fantasy......for Ricardo that line between the two is very thin indeed. Do not, repeat , do not base any investment decisions on the above ramblings of this individual.

  • ricardouno by ricardouno May 13, 2015 7:26 AM Flag

    Ricardo would like to add, at this time, a term to the medical therapeutic lexicon. It is, "CD30 Depletion Therapy".

    It references the treatment of autoimmune and inflammatory disease states with agents that deplete CD30+ lymphocytes.

    My question is: Has Ricardo gone totally bonkers? Is there hope for him......and, importantly, do you feel that this new term will ever find its way, in the future, into the established language of therapeutic medicine?

    Best of luck to all !



    Disclosure: Ricardo has a humongous long term position in the shares of SGEN. His opinions are, therefore, to be considered as totally biased. Listen to him only at your own peril. OK, you get the picture.

  • Reply to

    Ricardo - UCLA chair of Neurosurgery on NWBO

    by nhanduyvo Mar 9, 2015 6:22 PM
    ricardouno ricardouno Mar 9, 2015 10:29 PM Flag


    Yes, they do seem to be excited about this at UCLA.

    See also the videos at:

    I have a long term position in nwbo. Still consider it quite risky and speculative, but the confidence in the results being reportedly witnessed by physicians at a leading medical center in encouraging.

    Good luck!


  • AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal

42.25+1.01(+2.45%)Aug 28 4:00 PMEDT